830 related articles for article (PubMed ID: 27390295)
1. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.
Castelino FV; Seiders J; Bain G; Brooks SF; King CD; Swaney JS; Lorrain DS; Chun J; Luster AD; Tager AM
Arthritis Rheum; 2011 May; 63(5):1405-15. PubMed ID: 21305523
[TBL] [Abstract][Full Text] [Related]
4. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
[TBL] [Abstract][Full Text] [Related]
8. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
[TBL] [Abstract][Full Text] [Related]
9. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
[TBL] [Abstract][Full Text] [Related]
10. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).
Kanno Y; Kawashita E; Kokado A; Okada K; Ueshima S; Matsuo O; Matsuno H
Arthritis Rheum; 2013 Feb; 65(2):492-502. PubMed ID: 23124680
[TBL] [Abstract][Full Text] [Related]
11. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
12. Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment.
Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Norose T; Katsumata Y; Masuda I; Yamanaka H; Morohoshi T; Kawaguchi Y
Arthritis Res Ther; 2019 Apr; 21(1):103. PubMed ID: 30999934
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression.
Nakayama W; Jinnin M; Tomizawa Y; Nakamura K; Kudo H; Inoue K; Makino K; Honda N; Kajihara I; Fukushima S; Ihn H
Rheumatology (Oxford); 2017 Jan; 56(1):145-155. PubMed ID: 27744356
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Ohashi T; Yamamoto T
Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts.
Agarwal SK; Wu M; Livingston CK; Parks DH; Mayes MD; Arnett FC; Tan FK
Arthritis Res Ther; 2011 Jan; 13(1):R3. PubMed ID: 21223583
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
18. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
19. The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.
Ikawa T; Ichimura Y; Miyagawa T; Fukui Y; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
J Invest Dermatol; 2022 Jun; 142(6):1541-1551.e3. PubMed ID: 34838790
[TBL] [Abstract][Full Text] [Related]
20. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.
Song Y; Zhu L; Li M
Clinics (Sao Paulo); 2013 Oct; 68(10):1350-7. PubMed ID: 24212843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
